BURLINGTON, Mass.--(BUSINESS WIRE)--Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the majority of surveyed U.S. oncologists (57 percent) identified FOLFIRINOX* as the most efficacious treatment for advanced pancreatic cancer, when compared to other currently available agents. Patients with advanced pancreatic cancer who received FOLFIRINOX experienced a considerably longer median overall survival compared with patients who received gemcitabine (Eli Lilly’s Gemzar, generics) monotherapy.
